Novel Pharmacological Approaches in Migraine Therapy

Migraine is a prevalent and debilitating neurological disorder, recognized as one of the leading causes of disability worldwide, particularly affecting individuals under the age of fifty. Characterized by recurrent, severe headaches often accompanied by symptoms such as nausea, vomiting, and heightened sensitivity to sensory stimuli, migraines significantly impact the quality of life. The pathophysiology of migraines involves the activation of nerve fibers in the meninges, yet the precise triggers and mechanisms remain partially understood. Historically, the treatment landscape for migraines has been limited, relying on medications repurposed from other therapeutic areas, which often resulted in suboptimal efficacy and undesirable side effects. However, recent advancements in pharmacological research have identified the calcitonin gene-related peptide (CGRP) as a pivotal player in migraine pathophysiology. This has led to the development of targeted therapies, including CGRP-receptor antagonists and monoclonal antibodies, which have shown promise in clinical trials. Despite these advancements, there remain unanswered questions regarding the long-term management of migraines and the integration of these novel therapies into clinical practice.

This research topic aims to explore novel pharmacological approaches in migraine therapy, focusing on the latest advancements and ongoing challenges in the field. The objective is to address key questions related to the efficacy, safety, and regulatory aspects of emerging treatments, as well as to investigate the underlying pathophysiological mechanisms of migraines. By doing so, the research seeks to enhance our understanding of migraine management and improve patient outcomes.

To gather further insights in the evolving landscape of migraine therapy, we welcome articles addressing, but not limited to, the following themes:

- The role of CGRP in migraine pathophysiology and its implications for treatment.
- Clinical efficacy and safety of CGRP-receptor antagonists and monoclonal antibodies.
- Comparative studies of novel therapies versus traditional migraine treatments.
- Mechanisms of action and potential side effects of new pharmacological agents.
- Regulatory challenges and considerations in the approval of migraine therapies.
- Patient adherence and quality of life improvements with novel treatments.
- Exploration of endogenous and exogenous triggers in migraine pathogenesis.

Keywords: Chronic migraine, CGRP, monoclonal antibodies, ditans, onabotulinumtoxin A, regulatory aspects

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.